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Background: This retrospective study assessed the use and long-term outcome
of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with severe
autoimmune diseases (ADs), reported to the European Society for Blood and Marrow
Transplantation (EBMT) registry.
Methods: Between 1997 and 2014, 128 patients received allogeneic HSCT for various
hematological (n = 49) and non-hematological (n = 79) refractory ADs. The median age
was 12.7 years (0.2–62.2). Donors were syngeneic for seven, matched related for 46,
unrelated for 51, haploidentical for 15, and cord blood for nine patients.
Results: The incidence of grades II-IV acute graft-vs.-host disease (GvHD) was 20.8%
at 100 days. Cumulative incidence of chronic GvHD was 27.8% at 5-years. Non-relapse
mortality (NRM) was 12.7% at 100-days. Overall survival (OS) and Progression-Free
Survival (PFS) were 70.2 and 59.4% at 5-years, respectively. By multivariate analysis,
age <18 years, males, and more recent year of transplant were found to be significantly
associated with improved PFS. Reduced conditioning intensity was associated with a
lower NRM. On a subgroup of 64 patients with detailed information a complete clinical
response was obtained in 67% of patients at 1-year.
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Conclusions: This large EBMT survey suggests the potential of allogeneic HSCT to
induce long-term disease control in a large proportion of refractory ADs, with acceptable
toxicities and NRM, especially in younger patients.
Keywords: allogeneic hematopoietic stem cell transplantation, autoimmune diseases, long-term outcome,
hematological autoimmune diseases, non-hematological autoimmune diseases
BACKGROUND
Allogeneic hematopoietic stem cell transplantation (HSCT) is a
potentially curative standard treatment for a variety of malignant
and non-malignant disorders (1). During the last decade major
changes have occurred in the field of HSCT (1–5). Limitations
for the transplant procedures have been modified because of the
introduction of less aggressive conditioning regimens, improved
patient selection, better supportive care, and recent advances
in graft-vs.-host disease (GvHD) prophylaxis, thus representing
an intriguing approach for patients affected by non-malignant
disorders and autoimmune diseases (ADs) (6–16).
Several studies have investigated the potential application of
autologous and allogeneic HSCT to control otherwise resistant
disease activity in severe ADs (9, 17, 18). In particular,
the rationale for autologous HSCT in ADs has been to
ablate and reset the autoreactive immune system (9, 18–20).
However, some patients may develop disease flares resulting
either from incomplete eradication of autoreactive memory
cells or re-induction of autoimmunity driven by genetic
predisposition (9, 20).
For patients with refractory ADs, allogeneic HSCT offers a
more potent eradication of autoreactive cells, achieved through
the conditioning regimen, combined with the replacement
by a new donor immune system, with the potential to
develop tolerance to both allo- and auto-antigens (21–23).
Nevertheless, allogeneic HSCT has been a rare treatment
option for ADs compared with autologous HSCT (18, 24–
31). The area where allogeneic HSCT has mostly been
used has been immune cytopenia (27). Some patients clearly
benefited from this treatment (31), despite considerable toxicity
and non-relapse mortality (NRM) reported in the past (9,
18). The rationale for the use of allogeneic HSCT has
gained additional traction more recently, as monogenic defects
associated with autoimmunity and immunodeficiency have been
identified (32–37).
The European Society for Blood and Marrow Transplantation
(EBMT) Autoimmune Diseases (ADWP), Inborn Errors
(IEWP) and Pediatric (PDWP) Working Parties conducted a
retrospective survey to analyze long-term disease outcome and
toxicity of allogeneic HSCT in refractory ADs patients.
METHODS
Study Design
This study is a retrospective multicenter study analyzing EBMT
registry data. Additional information was collected using a
specific questionnaire. The study was approved by the ADWP
and participating EBMT centers reported data from patients
affected by ADs (hematological and non-hematological ADs),
including those with autoinflammatory and genetic components,
who had been treated with allogeneic HSCT from the first
registration in 1997 to the end of 2014. Patients with a previous
allogeneic HSCT for a conventional hematological indication
have been included. Patients transplanted for a malignant
hematological disease with a concomitant AD were excluded
from the analysis. All EBMT teams are required to obtain
signed informed consent for transfer of anonymized data via
standardized minimal essential data forms in accordance with
data protection regulations.
The following variables were analyzed from the EBMT
database: patient gender, patient age at transplantation, disease
classification at time of diagnosis according to primary disease
established criteria, conditioning regimen, graft characteristics,
incidence of acute, and chronic GvHD.
In addition, long-term side effects (secondary autoimmune
disease or malignancy, viral reactivations), previous and post-
transplant treatments, and disease status at last follow-up
were analyzed in the subgroup of 64 patients with completed
questionnaires. Disease characteristics (severity, refractoriness to
standard treatments, revision and reclassification of all diagnoses
in view of the spectrum of pediatric ADs, including those with
autoinflammatory and overlap with other genetic diseases and
inborn errors) were assessed by local physician.
Definitions
All outcomes were measured from the time of stem cell infusion.
Engraftment was defined as a persistent blood cells count
above a predefined level (neutrophils >0.5 × 109/l per three
consecutive days and platelets >20 × 109/l, unsupported by
transfusions, for 3 days), starting from the day of transplantation.
Progression-free survival (PFS) was defined as survival without
evidence of disease reactivation.
The response to transplant for immune cytopenia was defined
according to the following criteria: complete remission (CR) for
the normalization of blood counts with hemoglobin >12 g/dL,
neutrophils >1.5 × 109/L and platelets >150 × 109/L; partial
remission (PR) for hemoglobin >8 and ≤12 g /dl, neutrophils
>0.5 × 109/L, and ≤1.5 × 109/L and platelets >50 × 109/L
and ≤150 × 109/L; active disease for level ≤8 g /dl, neutrophils
≤0.5 × 109/L and platelets ≤50 × 109/L) (30). For AD other
than cytopenias response was assessed by local physician based
on the following classification: complete remission in the absence
of all clinical and laboratory autoimmune disease activity); partial
remission for low disease activity with persistence of minor
disease specific symptoms; active disease in case of no response
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or response not fulfilling CR/PR criteria. Failure to respond was
assessed according to the above criteria by the local physician
in charge of the AD based on an inability to achieve a PR or
CR at any time point. Major relapse was assessed according to
the above criteria by the local physician in charge of the AD
based on progression from a CR or PR to active disease. Minor
relapse was assessed according to the above criteria by the local
physician in charge of the AD based on progression from a CR to
a PR. These criteria applied irrespective of the AD (i.e., include
immune cytopenias).
Overall survival (OS) was defined as the time from allogeneic
HSCT to death, regardless of the cause. NRM was defined as
death without evidence of relapse or progression.
Statistics
The probabilities of OS and progression-free survival (PFS)
were calculated by using the Kaplan-Meier method. Cumulative
incidence was used to estimate the following endpoints:
NRM, relapse incidence (RI), acute and chronic GvHD,
to accommodate for competing risks. To study acute and
chronic GvHD, we considered relapse and death to be
competing events.
Multivariate analysis included all variable associated with one
endpoint in univariate analysis: AD diagnosis (hematological vs.
non-hematological diseases), sex, age at HSCT (cut-off 18 years),
donor type (matched related donor vs. others), year of HSCT
(before or after 2009), conditioning regimen (myeloablative vs.
reduced-intensity conditioning) and GvHD prophylaxis (ex-vivo
or in-vivo T-cell depletion). Results were expressed as the hazard
ratio (HR) with the 95% confidence interval (95% CI). Statistical
analyses were performed with SPSS 24.0 (SPSS Inc., Chicago, IL,
USA) and R 3.4.0 (38).
RESULTS
Overall Population and Main Transplant
Outcomes
Patients and HSCT Characteristics
Between 1997–2014 inclusive, 128 patients received allogeneic
HSCT for various hematological (n= 49) and non-hematological
(n= 79) refractory AD. Disease and transplant characteristics are
summarized in Tables 1, 2. Patients were treated at 63 centers in
21 countries (Table 3).
Themedian age of patients at HSCTwas 12.7 years (range 0.2–
62.2). Eighteen patients received a previous transplant, mainly
autologous HSCT (n = 15). Median time from diagnosis to
transplant was 3.8 years (range 0.01–27.2). Median follow-up was
49 months (range 21–87).
Donors were matched related donors (MRD) for 46 patients,
unrelated donors (UD) for 51, mismatched related donor
(MMRD) for 15, unrelated cord blood for nine, and syngeneic
for seven patients.
The graft source was peripheral blood stem cells (PBSCs)
in 67, bone marrow (BM) in 52, and cord blood in
nine patients.
Conditioning was classified (39) as myeloablative (MAC)
in 74 and reduced-intensity (RIC) in 48 patients. Total body
TABLE 1 | Disease classification (overall population; n = 128).
Overall population (n = 128) N (%)
Non hematological disorders, n = 79 (61.7%)
MS 4 (3.1%)
SLE 5 (3.9%)
Other CTD 2 (1.6%)
Wegener 1 (0.8%)
Behcet 2 (1.6%)
Other vasculitis 5 (3.9%)
RA 2 (1.6%)
JIA 13 (10.2%)
CIDP 1 (0.8%)
NMO 5 (3.9%)
Other neurological disorders 2 (1.6%)
Crohn’s disease 7 (5.5%)
Other IBD 13 (10.2%)
Other Ads 17 (13.3%)
Hematological disorders, n = 49 (38.3%)
ITP 6 (4.7%)
AIHA 11 (8.6%)
Evans syndrome 15 (1.8%)
Other non-malignant hematological disorders 17 (13.3%)
The table includes details about disease characteristics of all the patients, divided as
“hematological disorders” and “non-hematological disorders.” MS, multiple sclerosis;
SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; JIA, juvenile idiopathic
arthritis; CIDP, chronic inflammatory demyelinating polyneuropathy; NMO, neuromyelitis
optica; ITP, Immune thrombocytopenia; AIHA, autoimmune hemolytic anemia; IBD,
inflammatory bowel disease; ADs, autoimmune diseases; CTD, connective tissue disease.
irradiation (TBI) was included in the conditioning regimen for 15
patients. Busulfan-based regimen was used in 35 patients, while
24 patients received a treosulfan-based regimen.
Ex-vivo T-cell depletion (TCD) was performed in 14 cases.
Serotherapy with anti-thymocyte globulin (ATG) was given in 41
patients and with alemtuzumab in 46 patients. Post-transplant
GvHD prophylaxis was given in 115 patients, mainly based
on cyclosporine, associated either with methotrexate (27%) or
mycophenolate mofetil (41%).
Engraftment and Graft Rejection
All except seven patients experienced sustained donor
cell engraftment.
Engraftment (see Methods) was obtained in all patients
within a median of 14.5 days from HSCT, both for
neutrophils and platelets. Graft failure was reported in seven
patients, thus resulting in an overall primary graft failure
rate of 5.5%.
GvHD
In all, 53 out of 128 patients developed acute GvHD, and the
incidence of grades II-IV acute GvHD was 20.8% (95% CI: 14.1–
28.5) at 100-days. Nine patients reported grades III-IV acute
GvHD. Cumulative incidence of chronic GvHD was 27.8% (95%
CI: 19.3–36.9) at 5-years.
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TABLE 2 | Transplant details (overall population; n = 128).
Variables Number of patients %
Donor
MRD 46 35.94
UD 51 39.84
MMRD 15 11.72
Syngeneic 7 5.47
Cord blood 9 7.03
Stem Cell Source
Peripheral blood 67 52.34
Bone marrow 52 40.62
Cord blood 9 7.03
Conditioning regimen
RIC 48 39.34
MAC 74 60.66
Missing information 6
Ex-vivo manipulation
No 114 89.06
Yes 14 11.67
In vivo TCD
No 32 26.89
Yes: 87 73.11
ATG 41
Alemtuzumab 46
Missing 9
Post-transplant GvHD prophylaxis 115 89.84%
CSA 21
CSA+MTX 31
CSA+ MMF 47
Tacrolimus + MMF 2
Tacrolimus + MTX 4
PT-Cy 2
Other 8
Missing information 8
The table includes details about the graft and the conditioning regimen for all the patients.
MRD, Matched related donor; UD, unrelated donor; MMRD, Mismatched related donor;
RIC, reduced-intensity; MAC, myeloablative; TCD, T-cell depletion; ATG, anti-thymocyte
globulin; CSA, cyclosporine; MMF, mycophenolate mofetil; MTX, methotrexate; PT-Cy,
post-transplant cyclophosphamide.
Survival and Risk Factors for Outcome
Relapse incidence (Figure 1) was 18.1 % (95% CI: 11.4–26.1) at
3-years and 20% (95% CI: 12.6–28.7) at 5-years. PFS was 59.4% at
5-years (95% CI: 49.9–69). NRM (Figure 2) was 12.7% (95% CI:
7.6–19.2) at 100-days, and 20.5% at 5-years (95% CI: 13.8–28.2).
The OS was 70.2% (95% CI: 61.5–78.9) at 5-years.
Significant associations were observed by univariate analysis.
Higher NRM (28.7 vs. 12.3%; p = 0.02) and lower PFS (49
vs. 73.3%; p = 0.02) were registered in females. Adult patients
presented higher RI (31.2% vs. 10.3%; p= 0.002), lower PFS (46.8
vs. 69.8%; p = 0.009) and higher rates of acute GvHD (42.2 vs.
21.3%; p= 0.005) as compared with children. A more recent year
of transplant was associated with higher PFS (71.6 vs. 50.4%; p
= 0.008) and lower rates of acute GvHD (16.3 vs. 38.8%; p =
0.007). Non-hematological disorders showed a trend toward a
TABLE 3 | Center distribution by country (overall population; n = 128).
Center Number of patients %
United Kingdom 42 33
Germany 16 13
Italy 13 10
Netherlands 10 8
Spain 5 4
Russia 2 2
Belgium 2 2
France 6 5
Switzerland 2 2
Turkey 9 7
Hungary 3 2
Czech Republic 2 2
Israel 2 2
Austria 4 3
Sweden 4 3
Norway 1 1
Portugal 1 1
Belarus 1 1
Lithuania 1 1
Poland 1 1
Lebanon 1 1
Total 128 100%
Details of the 63 participating centers from 21 European countries. The predominant
country of activity was United Kingdom, who made up 33% of the activity.
better OS (77.9 vs. 62.9%; p= 0.05). Lower rates of chronic GvHD
were reported in HSCT from MRD (11.7 vs. 26%; p = 0.04). No
significant association was reported for ATG or alemtuzumab.
A multivariate analysis (Table 4) of prognostic factors was
performed. Age more than 18 years was associated with a higher
RI (HR: 3.72; 95% CI: 1.38–10; p = 0.009), a higher incidence of
chronic GvHD (HR: 3.75; 95% CI: 1.67–8.39; p = 0.001) and a
lower PFS (HR: 2.07; p = 0.02). A more recent year of transplant
was associated with a lower NRM (HR: 0.86; p = 0.003 and
chronic GvHD (HR: 0.88; p = 0.009); a better PFS (HR: 0.9; p
= 0.01) and OS (HR: 0.89; p = 0.003). Females were associated
with a higher NRM (HR: 3.94; p = 0.008) and lower PFS (HR:
2.5; p = 0.009) and OS (HR: 2.61; p = 0.02). RIC regimen was
associated with a lower NRM (HR: 0.31; p = 0.02). MRD was
associated with a lower incidence of acute GvHD (HR = 0.24,
95%CI: 0.08–0.75; p= 0.01). There was no significant association
with diagnosis and centers.
Subgroup of 64 Patients With Additional
Information
Among the total 128 patients who received allogeneic HSCT
between 1997 and 2014, we received detailed questionnaires
on long-term outcomes from 64 patients. These patients were
treated at 24 centers in 13 countries (United Kingdom, Italy,
Germany, Spain, Russia, Belgium, France, Switzerland, Turkey,
Hungary, Lebanon, Canada and Czech Republic).
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FIGURE 1 | Relapse incidence (RI) and progression-free survival (PFS). RI and PFS in overall population (n = 128) are shown in (A,B) respectively.
FIGURE 2 | OS and cumulative incidence of NRM. OS and cumulative incidence of NRM in overall population (n = 128) are shown in (A,B), respectively.
Disease characteristics for this cohort of patients are shown
in Table 5; in view of the spectrum of pediatric ADs, including
those with autoinflammatory and overlap with other genetic
diseases and inborn errors, all diagnoses were reviewed and
classified accordingly.
The diagnosis of AD was hematological (n = 21) and non-
hematological (n= 43), among pediatric (n= 45) and adult (n=
19) populations. The median age of patients at HSCT was 11.14
years (range 1.22–51.57).
All patients were refractory to previous immunosuppressive
therapies (median of four lines of treatments, range 1–13),
including cyclophosphamide (n = 16), biological therapies (n
= 41, including rituximab in 20 patients and infliximab in 14),
cytotoxic drugs (n = 30), oral immunosuppression (n = 37),
intravenous immunosuppression (n = 22), and others (n =
29). Median time from diagnosis to transplant was 5 months
(range 0.3–27).
Eight patients (12%) had received a previous autologous
transplant. Two patients received an allogeneic HSCT for a
conventional hematological indication in the past (Non-Hodgkin
Lymphoma and Severe Aplastic Anemia).
The graft source was PBSCs in 38, BM in 24, and cord blood
in two patients. Donor sources were as follows; 41% MRD (n =
26), 42% UD (n= 27), 9%MMRD (n= 6), 5% syngeneic (n= 3),
and 3% cord blood (n= 2). Median CD34+ and CD3+ cell doses
infused were 6.52× 106/Kg and 192.1× 106/Kg, respectively.
Conditioning was MAC in 35 and RIC in 29 patients. A
fludarabine-based regimen was used in 50 (80%) patients, in
association with treosulfan for 17 patients, melphalan for 14
patients, and cyclophosphamide for 11 patients. Nine patients
received TBI. Ex-vivo TCD was performed in seven cases.
Serotherapy with ATG was given in 16 patients, while 30 patients
received alemtuzumab. Post-transplant GvHD prophylaxis was
cyclosporine-based for the majority of patients (n = 54), with
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TABLE 5 | Reviewed disease classification (selected cohort of patients; n = 64).
Selected population (n = 64) N (%)
Non-hematological disorders, n = 43 (67.2%)
SLE 3 (4.7%)
Cq1 deficiency (SLE) 1 (1.6%)
GPA /Wegener’s granulomatosis 1 (1.6%)
Behcet’s disease 1 (1.6%)
RA 1 (1.6%)
JIA 7 (10.9%)
NMO 4 (6.3%)
Crohn’s disease 5 (7.8%)
Other IBD 4 (6.3%)
IPEX syndrome 1 (1.6%)
Multi-systemic inflammatory disease syndrome 3 (4.7)%
Lichen myxoedematosus 1 (1.6%)
MKD/TRAPS polymorphism 1 (1.6%)
Glanzmann’s Thrombasthenia 1 (1.6%)
Njimegen Breakage Syndrome 1 (1.6%)
Tricohepatoenteric syndrome 1 (1.6%)
Other Ads 7 (10.9%)
Hematological disorders, n = 21 (32.8%)
ITP 2 (3.1%)
AIHA 7 (10.9%)
Evans syndrome 9 (14.1%)
Severe B-, T-, NK-cell immunodeficiency 1 (1.6%)
SCID 1 (1.6%)
PWCA 1 (1.6%)
The table includes details about disease characteristics of the selected cohort of
patients with more detailed characteristics (n = 64), divided as “hematological disorders”
and “non-hematological disorders.” In view of the spectrum of pediatric ADs, all
diagnoses were reviewed and classified according to the study questionnaire. AIHA,
autoimmune hemolytic anemia; ITP, immune thrombocytopenia; JIA, juvenile idiopathic
arthritis; SCID, severe combined immuno deficiency; IPEX, immune dysregulation,
polyendocrinopathy, enteropathy, X-linked; GPA, granulomatosis with polyangiitis; NMO,
neuromyelitis optica; RA, rheumatoid arthritis; PWCA, pure white cell aplasia; TRAPS, TNF
receptor-associated periodic syndrome; IBD, inflammatory bowel disease; SLE, systemic
lupus erythematosus; ADs, autoimmune diseases; MKD, mevalonic kinase deficiency.
the addition of mycophenolate mofetil (MMF) in 33 cases;
four patients received tacrolimus, and two patients were treated
with sirolimus.
Treatment-Related Complications
GvHD
The incidence of grades II-IV acute GvHD was 16.4% (95% CI:
8.4–26.8) at 100-days; severe acute GvHD was reported only
in four patients. Cumulative incidence of chronic GvHD was
32.5% (95% CI: 20.8–44.8) at 5-years; extensive manifestations
of chronic GvHD were reported in 11 patients. In univariate
analysis the incidence of chronic GvHD was significantly lower
in patients receiving in-vivo TCD (24.3 vs. 52.9%; p= 0.02).
Secondary autoimmune diseases
Seven patients (11.3%) developed secondary autoimmune
diseases, distinct from their primary disease, at a median time of
15 months (7.9–43.8), including autoimmune thrombocytopenia
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(n = 1), autoimmune thyroid diseases (n = 3), psoriasis (n
= 1), autoimmune hemolytic anemia (AIHA n = 1), Guillain-
Barré syndrome (n = 1), and other secondary AD not otherwise
specified (n= 1).
New malignancies
One case of new malignancy (lymphoma) was reported at 62
months post-transplant.
Infections
Viral reactivations were reported in a total of 33 patients,
including Cytomegalovirus (CMV; n = 14), Epstein-Barr Virus
(EBV; n = 10), Adenovirus (n = 5), polyoma BK virus (n = 3;
hemorrhagic cystitis in two cases), Herpes Simplex Virus (HSV, n
= 2), Human Herpesvirus 6 (HHV6; n= 3), and Varicella-Zoster
Virus (VZV; n = 2). Seven cases of invasive fungal infection
were reported (on which one aspergillosis and three candidiasis).
Ten bacterial infections (only four patients developed infection
from Gram-negative bacteria) were observed and five patients
developed pneumonia. Renal failure was reported in four cases.
Other adverse events were reported in the long-term follow-up
of these patients: severe post-transplant lymphopenia (n = 1),
severe osteopenia (n = 2; possibly due to prolonged previous
treatment with steroids), renal plus liver impairment (n = 1),
cerebral hemorrhage (n = 1), chronic lung disease (n = 1),
multi-organ failure (MOF; n= 2).
Long-Term Response to Treatment
At the time of transplantation, all patients had active disease
refractory to standard therapy. Median follow-up was 67 months
(IQR 36.5–104 months). At 100 days post-HSCT, response
was achieved in 79% of patients (complete remission in 39
patients, partial remission in 10 patients). At the last follow-
up complete clinical response of refractory AD was obtained in
67.2% of patients (n = 43), while partial remission was reported
in 6.3% (n= 4).
Incidence of relapse/progression was 20.3% (95% CI: 10.6–
32.2) at 5 years, with no differences between immune cytopenia
(16.2%) and other ADs (20.6%). Post-HSCT autoimmune disease
specific treatment was required for 12 patients, mainly based
on steroids (n = 7), in combination with rituximab (n = 2),
intravenous immunoglobulins (n = 1), bortezomib (n = 1),
MMF (n = 2), cyclophosphamide (n = 1). Adalimumab (n = 1),
plasmapheresis (n = 1) or second allogeneic HSCT (n = 1) were
also reported.
At last follow-up 39 patients are progression and
immunosuppression-free survivors.
Long-Term Outcomes
Results confirmed those found in the entire population. OS
was 76% at 5-year (95% CI: 64.8–87.3). The primary cause of
death was divided between disease (progression of AD; n = 6),
NRM (n = 9; seven patients succumbed to infections, and two
with MOF). All causes of death classified by local physician as
NRM, were related to drug toxicity and transplant; none of these
patients experienced disease recurrence or received AD specific
treatment after HSCT. Cumulative incidence of NRM was 14.9%
at 5-year (95% CI: 7.3–25.1) and PFS was 64.8% at 5-year (95%
CI: 52.1–77.6).
By univariate analysis, there was no significant differences
between immune cytopenia and other ADs in terms of RI
(16.2 vs. 18.6%, respectively, p = 0.91), OS (76.2 vs. 79.9%),
respectively, p= 0.59) and PFS (73.8 vs. 64.3%, p= 0.63). Amore
recent year of transplant, after 2009, was significantly associated
with improved outcomes: higher PFS (76.3 vs. 55.6%; p = 0.03),
higher OS (90.7 vs. 64.3%; p = 0.005), and lower rates of chronic
GvHD (19 vs. 48.1%; p= 0.01).
DISCUSSION
This multicenter report presents the largest analysis of long-
term outcomes of allogeneic HSCT in a range of severe ADs,
including several patients with increasingly characterized
monogenic diseases associated with autoimmunity and
immunodeficiency (40, 41).
At the last follow-up, in this heterogeneous group of patients
with severe and refractory ADs, long-term complete clinical
response was obtained in 67.2% of patients. Response was
independent of the underlying disease (hematological vs. non-
hematological AD). These data required further exploration,
possibly within a prospective study.
The majority of patients underwent matched related or
unrelated donor HSCT, which is generally considered the
lowest risk allogeneic transplant strategy with best outcomes.
Overall, NRM was 20.5% at 5-years, but this had plateaued
by 2 years post-transplant. These results in patients with
refractory and heavily pre-treated diseases (with some patients
having already received a previous autologous HSCT) are
in keeping with outcomes of allogeneic HSCT in other
hematological diseases, and supportive of further exploration
for selected patients with high risk ADs with a poor prognosis
despite other immunomodulatory treatments including
biological therapies and autologous HSCT. Potential candidates
could be patients suffering a potentially life-threatening
ADs with existing risk factors for an unfavorable outcome
from their AD combined with low-risk factors for NRM
[younger age, identical sibling or well-matched unrelated
donor and low hematopoietic cell transplantation-specific
comorbidity index (42)], and, in particular, in ADs with strong
genetic predisposition.
Over the several decades, outcomes of allogeneic HSCT
across all indications have improved due to a variety of factors,
including better patient selection, donor-recipient matching and
transplant techniques (1, 2, 13, 15, 16). Likewise, multivariate
analysis confirmed chronological improvement in outcomes
in our AD study population, especially in younger patients,
supporting a “learning curve.” However, in our analysis the
intensity of the conditioning regimen had no substantial
association with outcomes, and, similarly, we failed to document
a strong influence of donor type (between matched and
mismatched donors). Nevertheless, the heterogeneity and small
numbers of the study population limited the power of these
comparisons. This area warrants further exploration given the
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potential impact of transplant technique and donor-recipient
matching on the incidence of short and long-term complications.
In particular, the incidence and type of “late effects” after
allogeneic HSCT in this setting is a novel feature of this analysis.
Preparative regimens were relatively well-tolerated with limited
regimen-related toxicity. Although there was no coordinated
prospective comprehensive long-term follow-up within this
group of patients, late complications were identified through a
detailed questionnaire designed for this retrospective study. The
spectrum of complications included 33 viral reactivations and
one case of secondary malignancy. We also observed seven cases
of a distinct secondary autoimmune disease, which is likely to
be above the level reported follow HSCT in other contexts (43–
46). A prospective study is necessary to identify the potential
risk factors for the development of post-transplant AD, including
details about donor chimerism and concomitant GvHD.
GvHD is also an important consideration in non-malignant
indications, such as ADs. Reduction of GvHD, and potentially a
mitigation of the graft-vs.-tumor (GvT) effect, is often associated
with an increase in relapse in patients with hematologic
malignancies; however, the occurrence of GvHD is considered
an unacceptable toxicity in ADs as a GvT effect is not
necessary in non-malignant diseases [9, 17. 31]. We reported
an incidence of grades II-IV acute GvHD of 20.8% at 100-
days and cumulative incidence of chronic GvHD of 27.8% at
5-year. By promoting bidirectional transplantation tolerance, PT-
Cy strategy or alternative graft manipulation strategies (i.e., αβ
T cell-depleted grafts) could further improve GvHD rates and
broaden the therapeutic possibilities also in patients with ADs
(8, 14, 47, 48).
Moreover, animal models at least suggest that remission
of experimental AD can be achieved after non-myeloablative
conditioning with mixed chimerism (43, 49, 50). Unfortunately,
we did not have detailed data about the chimerism status
and could not clearly prove the hypothesis that remission is
independent of a complete engraftment of the donor immune
system. However, with RIC regimens, which generally lead to a
state of mixed chimerism in early post HSCT phase, PFS, and
relapse incidence were comparable to MAC regimens.
Allogeneic HSCT combines high-dose cytotoxic therapy,
donor-vs.-host alloreactivity together with replacement of a
dysfunctional immune system by regenerating healthy donor
immune system, with potential tolerance to allo- and auto-
antigens. It is also reasonable to hypothesize that a subclinical
graft-vs.-host reaction might help to eradication autoreactive
B and T cells surviving the conditioning regimen, through
the so-called graft-vs.-autoimmunity (GvA) effect, which has
been observed in animal models (23). Unfortunately, more
detailed immunological data, including donor chimerism and
post-transplant immune-reconstitution, were not available in this
study. In the future, fostering prospective biobanking (51) of ADs
patients undergoing HSCT could enable detailed immunological
analysis to further elucidate this hypothesis.
When interpreting the results of our analyses, we recognize
that there are limitations such as its retrospective nature and the
limited number of patients, together with the lack of uniformity
in transplant protocols and follow-up process. These findings
support the need to conduct prospective clinical trials to further
investigate the role of allogeneic HSCT for severe treatment
refractory or otherwise poor-risk ADs.
The limits of our study prevent us from addressing a
definitive role for this therapeutic strategy as compared to
alternative options. However, these results of this EBMT survey
suggests the potential of allogeneic HSCT to achieve long-
term disease remission in a large proportion of refractory ADs,
with predictable toxicities, especially in younger patients, with
improved outcomes in recent years.
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